Phase 1, Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07288814
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Plain-language summary
This Phase 1, Phase 2 trial is evaluating Mitoxantrone Hydrochloride Liposome & Enlonstobart as a treatment for people newly diagnosed with T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Mitoxantrone Hydrochloride Liposome & Enlonstobart (DRUG): Mitoxantrone hydrochloride liposome: ①Phase Ib：16 mg/m2、20 mg/m2 ，D1，q4w; ②Phase II：RP2D, D1，q4w, Up to 6 cycles Enlonstobart: 360mg，D1，q4w (The maintenance treatment phase is q3w), Up to 1 year
- Drugs / treatments
- Mitoxantrone Hydrochloride Liposome & Enlonstobart
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details